FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894912028> ?p ?o ?g. }

• W2894912028 endingPage "34627" @default.
• W2894912028 startingPage "34617" @default.
• W2894912028 abstract "// Marion Savina 1, 2, 3, 4 , Saskia Litière 5 , Antoine Italiano 6 , Tomasz Burzykowski 7 , Franck Bonnetain 8 , Sophie Gourgou 9 , Virginie Rondeau 3, 10 , Jean-Yves Blay 11, 12 , Sophie Cousin 6 , Florence Duffaud 13 , Hans Gelderblom 14 , Alessandro Gronchi 15 , Ian Judson 16 , Axel Le Cesne 17 , Paul Lorigan 18 , Joan Maurel 19 , Winette van der Graaf 20, 21, 23 , Jaap Verweij 22 , Simone Mathoulin-Pélissier 1, 2, 3, 4 and Carine Bellera 1, 2, 3, 4 1 Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux cedex 33076, France 2 INSERM CIC-EC 14.01 (Clinical Epidemiology), Bordeaux 33000, France 3 INSERM, ISPED, Centre INSERM U1219 Bordeaux Population Health Center, Epicene Team, Bordeaux 33000, France 4 University of Bordeaux, ISPED, Centre INSER M U1219 Bordeaux Population Health, Epicene Team, Bordeaux 33000, France 5 European Organisation for Research and Treatment of Cancer (EORTC), Brussels 1200, Belgium 6 Medical Oncology Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux cedex 33076, France 7 Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Hasselt University, Hasselt 3500, Belgium 8 Methodology and Quality of life in Oncology Unit, Besançon EA3181, France 9 Biometrics Unit, Institut du Cancer de Montpellier, Univ. Montpellier, Montpellier 34298, France 10 INSERM, ISPED, Centre INSERM U1219 Bordeaux Population Health Center, Biostatistic Team, Bordeaux 33000, France 11 Centre Léon Bérard, Comprehensive Cancer Center, Lyon 69008, France 12 University Claude Bernard Lyon I, Lyon 69000, France 13 Medical Oncology Unit, University Hospital La Timone and University of Aix-Marseille, Marseille 13005, France 14 Department of Medical Oncology, Leiden University Medical Center, Leiden 2300RC, The Netherlands 15 Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy 16 Institute of Cancer Research, Sutton, Surrey, United Kingdom 17 Medicine Department, Institut Gustave Roussy, Comprehensive Cancer Center, Villejuif 94800, France 18 University of Manchester and Christie NHS Foundation Trust, Manchester M20 4BX, UK 19 Department of Medical Oncology, Hospital Clinic, CIBERehd, Translational Genomics and Targeted Therapeutics in Solid Tumors (IDIBAPS), Barcelona 08036, Spain 20 The Institute of Cancer Research, Sutton, London SM2 5NG, United Kingdom 21 Radboud University Medical Centre, Department of Medical Oncology, GA Nijmegen 6525, The Netherlands 22 Department of Medical Oncology, Erasmus University Medical Center, CE Rotterdam 3015, The Netherlands 23 Royal Marsden NHS Foundation Trust, Chelsea, London, United Kingdom Correspondence to: Carine Bellera, email: C.Bellera@bordeaux.unicancer.fr Keywords: sarcoma; surrogate endpoints; meta-analysis; randomized trial; survival Received: August 20, 2018      Accepted: September 13, 2018      Published: October 02, 2018 ABSTRACT Background: Alternative endpoints to overall survival (OS) are frequently used to assess treatment efficacy in randomized controlled trials (RCT). Their properties in terms of surrogate outcomes for OS need to be assessed. We evaluated the surrogate properties of progression-free survival (PFS), time-to-progression (TTP) and time-to-treatment failure (TTF) in advanced soft tissue sarcomas (STS). Results: A total of 21 trials originally met the selection criteria and 14 RCTs ( N = 2846) were included in the analysis. Individual-level associations were moderate (highest for 12-month PFS: Spearman’s rho = 0.66; 95% CI [0.63; 0.68]). Trial-level associations were ranked as low for the three endpoints as per the IQWiG criterion. Materials and Methods: We performed a meta-analysis using individual-patient data (IPD). Phase II/III RCTs evaluating therapies for adults with advanced STS were eligible. We estimated the individual- and the trial-level associations between then candidate surrogates and OS. Statistical methods included weighted linear regression and the two-stage model introduced by Buyse and Burzykowski. The strength of the trial-level association was ranked according to the German Institute for Quality and Efficiency in Health Care (IQWiG) guidelines. Conclusions: Our results do not support strong surrogate properties of PFS, TTP and TTF for OS in advanced STS." @default.
• W2894912028 created "2018-10-12" @default.
• W2894912028 creator A5001102421 @default.
• W2894912028 creator A5007163286 @default.
• W2894912028 creator A5011819733 @default.
• W2894912028 creator A5025935523 @default.
• W2894912028 creator A5028687949 @default.
• W2894912028 creator A5039306714 @default.
• W2894912028 creator A5042202815 @default.
• W2894912028 creator A5044397434 @default.
• W2894912028 creator A5045755661 @default.
• W2894912028 creator A5050773185 @default.
• W2894912028 creator A5051870782 @default.
• W2894912028 creator A5053304892 @default.
• W2894912028 creator A5060949051 @default.
• W2894912028 creator A5064556770 @default.
• W2894912028 creator A5065856111 @default.
• W2894912028 creator A5066380305 @default.
• W2894912028 creator A5066953797 @default.
• W2894912028 creator A5069095893 @default.
• W2894912028 creator A5081888839 @default.
• W2894912028 creator A5091114658 @default.
• W2894912028 date "2018-10-02" @default.
• W2894912028 modified "2023-09-25" @default.
• W2894912028 title "Surrogate endpoints in advanced sarcoma trials: a meta-analysis" @default.
• W2894912028 cites W1589920570 @default.
• W2894912028 cites W1810662963 @default.
• W2894912028 cites W1828438395 @default.
• W2894912028 cites W1882650898 @default.
• W2894912028 cites W1991875620 @default.
• W2894912028 cites W2027724894 @default.
• W2894912028 cites W2046633896 @default.
• W2894912028 cites W2052813039 @default.
• W2894912028 cites W2088074688 @default.
• W2894912028 cites W2091453908 @default.
• W2894912028 cites W2092722132 @default.
• W2894912028 cites W2094558159 @default.
• W2894912028 cites W2095645261 @default.
• W2894912028 cites W2098553441 @default.
• W2894912028 cites W2101073224 @default.
• W2894912028 cites W2101776780 @default.
• W2894912028 cites W2102347194 @default.
• W2894912028 cites W2108881270 @default.
• W2894912028 cites W2115099019 @default.
• W2894912028 cites W2122492414 @default.
• W2894912028 cites W2123286047 @default.
• W2894912028 cites W2126133903 @default.
• W2894912028 cites W2126251787 @default.
• W2894912028 cites W2126275851 @default.
• W2894912028 cites W2127637293 @default.
• W2894912028 cites W2136344041 @default.
• W2894912028 cites W2139689275 @default.
• W2894912028 cites W2151178846 @default.
• W2894912028 cites W2156098321 @default.
• W2894912028 cites W2160752563 @default.
• W2894912028 cites W2165252656 @default.
• W2894912028 cites W2166178367 @default.
• W2894912028 cites W2180418290 @default.
• W2894912028 cites W2293716668 @default.
• W2894912028 cites W2397053700 @default.
• W2894912028 cites W246286872 @default.
• W2894912028 cites W2513128159 @default.
• W2894912028 cites W2586913895 @default.
• W2894912028 cites W2733307304 @default.
• W2894912028 cites W2740402239 @default.
• W2894912028 cites W4294215472 @default.
• W2894912028 doi "https://doi.org/10.18632/oncotarget.26166" @default.
• W2894912028 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6195375" @default.
• W2894912028 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30349653" @default.
• W2894912028 hasPublicationYear "2018" @default.
• W2894912028 type Work @default.
• W2894912028 sameAs 2894912028 @default.
• W2894912028 citedByCount "9" @default.
• W2894912028 countsByYear W28949120282019 @default.
• W2894912028 countsByYear W28949120282020 @default.
• W2894912028 countsByYear W28949120282021 @default.
• W2894912028 countsByYear W28949120282022 @default.
• W2894912028 crossrefType "journal-article" @default.
• W2894912028 hasAuthorship W2894912028A5001102421 @default.
• W2894912028 hasAuthorship W2894912028A5007163286 @default.
• W2894912028 hasAuthorship W2894912028A5011819733 @default.
• W2894912028 hasAuthorship W2894912028A5025935523 @default.
• W2894912028 hasAuthorship W2894912028A5028687949 @default.
• W2894912028 hasAuthorship W2894912028A5039306714 @default.
• W2894912028 hasAuthorship W2894912028A5042202815 @default.
• W2894912028 hasAuthorship W2894912028A5044397434 @default.
• W2894912028 hasAuthorship W2894912028A5045755661 @default.
• W2894912028 hasAuthorship W2894912028A5050773185 @default.
• W2894912028 hasAuthorship W2894912028A5051870782 @default.
• W2894912028 hasAuthorship W2894912028A5053304892 @default.
• W2894912028 hasAuthorship W2894912028A5060949051 @default.
• W2894912028 hasAuthorship W2894912028A5064556770 @default.
• W2894912028 hasAuthorship W2894912028A5065856111 @default.
• W2894912028 hasAuthorship W2894912028A5066380305 @default.
• W2894912028 hasAuthorship W2894912028A5066953797 @default.
• W2894912028 hasAuthorship W2894912028A5069095893 @default.
• W2894912028 hasAuthorship W2894912028A5081888839 @default.
• W2894912028 hasAuthorship W2894912028A5091114658 @default.

• next